Neuronal network of panic disorder: The role of the neuropeptide cholecystokinin

Depression and Anxiety

Volumn 29, Issue 9, 2012, Pages 762-774

  Zwanzger, P ^a   Domschke, K ^a,b   Bradwejn, J ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

CCK 4; cholecystokinin; neuroanatomy; neurobiology; panic disorder

Indexed keywords

4 AMINOBUTYRIC ACID; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; NORADRENALIN; SEROTONIN;

AMYGDALOID NUCLEUS; CHROMOSOME 11P; CHROMOSOME 3P; CHROMOSOME 4P; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; LOCUS CERULEUS; NERVE CELL NETWORK; NEUROANATOMY; NONHUMAN; PANIC; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BRAIN; CHOLECYSTOKININ; HUMANS; MICE; NERVE NET; PANIC DISORDER; RATS; RECEPTORS, CHOLECYSTOKININ; SYNAPTIC TRANSMISSION;

EID: 84865861927     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.21919     Document Type: Review

References (179)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiat 1994; 51: 8-19.
2. Weissman MM, Bland RC, Canino GJ, et al. The cross-national epidemiology of panic disorder. Arch Gen Psychiat 1997; 54: 305-309.
3. Roy-Byrne PP, Stang P, Wittchen HU, et al. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Brit J Psychiat 2000; 176: 229-335.
4. Stein DJ, Hollander E,. Textbook of Anxiety Disorders. Washington, DC and London: The American Psychiatric Publishing; 2003.
5. Gorman JM, Kent JM, Sullivan GM, Coplan JD,. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiat 2000; 157: 493-505.
6. Grillon C,. Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology. Biol Psychiat 2002; 52: 958-975.
7. Mathew SJ, Price RB, Charney DS,. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet 2008; 148: 89-98.
8. Martin EI, Ressler KJ, Binder E, Nemeroff CB,. The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Clin Lab Med 2010; 30: 865-891.
9. Vanderhaeghen JJ, Signeau JC, Gepts W,. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 1975; 257: 604-605.
10. Rehfeld JF,. Neuronal cholecystokinin: one or multiple transmitters? J Neurochem 1985; 44: 1-10.
11. Beinfeld M,. Cholecystokinin and gastrin chemistry, distribution, release and activity. In:, Negro-Vilan A, Conn PM, editors. Peptide Hormones Effects and Mechanisms of Action. Boca Raton, FL: CRC Press Inc.; 1988: 41-77.
12. Rehfeld JF, Neilson FC,. Molecular form and regional distribution of cholecystokinin in the central and peripheral nervous system. In:, Bradwejn J, Vasar E, editors. Cholecystokinin and Anxiety: From Neuron to Behaviour. Austin: Springer-Verlag-RG; 1995: 33-56.
13. Moran TH, Robinson PH, Goldrich MS, McHugh PR,. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 1986; 362: 175-179.
14. Dourish CT, Hill DR,. Classification and function of CCKreceptors. Trends Pharmacol Sci 1987; 8: 207-208.
15. Bradwejn J, Koszycki D, Meterissian G,. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiat 1990; 35: 83-85.
16. Bradwejn J, Koszycki D, Bourin M,. Dose ranging study of the effects of cholecystokinin in healthy volunteers. J Psychiat Neurosci 1991; 16: 91-95.
17. Bradwejn J, Koszycki D, Shriqui C,. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiat 1991; 48: 603-610.
18. Koszycki D, Copen J, Bradwejn J,. Sensitivity to cholecystokinin- tetrapeptide in major depression. J Affect Disord 2004; 80: 285-290.
19. Katzman MA, Koszycki D, Bradwejn J,. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder. Depress Anxiety 2004; 20: 51-58.
20. Bradwejn J, Koszycki D,. The cholecystokinin hypothesis of anxiety and panic disorder. Ann NY Acad Sci 1994; 713: 273-282.
21. Bradwejn J, Koszycki D, Payeur R, et al. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am J Psychiat 1992; 149: 962-964.
22. van Megen HJ, Westenberg HG, den Boer JA, et al. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology 1997; 129: 357-364.
23. Zwanzger P, Eser D, Padberg F, et al. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress Anxiety 2003; 18: 140-143.
24. de, Montigny C,. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiat 1989; 46: 511-517.
25. Bradwejn J, Koszycki D,. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiat 1994; 151: 261-263.
26. Shlik J, Aluoja A, Vasar V, et al. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiat Neurosci 1997; 22: 332-340.
27. Flint AJ, Koszycki D, Vaccarino FJ, et al. Effect of aging on cholecystokinin-induced panic. Am J Psychiat 1998; 155: 283-285.
28. Eser D, Schule C, Baghai T, et al. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Psychopharmacology 2007; 192: 479-487.
29. Zwanzger P, Baghai TC, Schuele C, et al. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology 2001; 25: 699-703.
30. Zwanzger P, Eser D, Nothdurfter C, et al. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Pharmacopsychiatry 2009; 42: 266-269.
31. Kronenberg G, Berger P, Tauber RF, et al. Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry 2005; 38: 24-29.
32. Rupprecht R, Rammes G, Eser D, et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009; 325: 490-493.
33. Kellner M, Muhtz C, Stark K, et al. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results. Psychopharmacology 2005; 179: 310-315.
34. Strohle A, Feller C, Onken M, et al. The acute antipanic activity of aerobic exercise. Am J Psychiat 2005; 162: 2376-2378.
35. Strohle A, Graetz B, Scheel M, et al. The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects. J Psychiat Res 2009; 43: 1013-1017.
36. Kellner M, Muhtz C, Demiralay C, et al. The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPRgenotype. J Psychiat Res 2009; 43: 642-648.
37. Kramer MS, Cutler NR, Ballenger JC, et al. A placebo-controlled trial of L-365,260, a CCKBantagonist, in panic disorder. Biol Psychiat 1995; 37: 462-466.
38. Pande AC, Greiner M, Adams JB, et al. Placebo-controlled trial of the CCK-Bantagonist, CI-988, in panic disorder. Biol Psychiat 1999; 46: 860-862.
39. Handelmann GE, Beinfeld MC, O'Donohue TL, et al. Extra-hippocampal projections of CCK neurons of the hippocampus and subiculum. Peptides 1983; 4: 331-334.
40. Herbert H, Saper CB,. Cholecystokinin-, galanin-, and corticotropin-releasing factor-like immunoreactive projections from the nucleus of the solitary tract to the parabrachial nucleus in the rat. J Comp Neurol 1990; 293: 581-598.
41. Zaborszky L, Beinfeld MC, Palkovits M, Heimer L,. Brainstem projection to the hypothalamic ventromedial nucleus in the rat: a CCK-containing long ascending pathway. Brain Res 1984; 303: 225-231.
42. Palkovits M, Kiss JZ, Beinfeld MC, Brownstein MJ,. Cholecystokinin in the hypothalamo-hypophyseal system. Brain Res 1984; 299: 186-189.
43. Skirboll L, Hokfelt T, Rehfeld J, et al. Coexistence of substance P- and cholecystokinin-like immunoreactivity in neurons of the mesencephalic periaqueductal central gray. Neurosci Lett 1982; 28: 35-39.
44. Burgunder JM, Young WS 3rd,. The distribution of thalamic projection neurons containing cholecystokinin messenger RNA, using in situ hybridization histochemistry and retrograde labeling. Brain Res 1988; 464: 179-189.
45. Senatorov VV, Trudeau VL, Hu B,. Expression of cholecystokinin mRNA in corticothalamic projecting neurons: a combined fluorescence in situ hybridization and retrograde tracing study in the ventrolateral thalamus of the rat. Brain Res Mol Brain Res 1995; 30: 87-96.
46. Meyer DK, Beinfeld MC, Oertel WH, Brownstein MJ,. Origin of the cholecystokinin-containing fibers in the rat caudatoputamen. Science 1982; 215: 187-188.
47. Morino P, Mascagni F, McDonald A, Hokfelt T,. Cholecystokinin corticostriatal pathway in the rat: evidence for bilateral origin from medial prefrontal cortical areas. Neuroscience 1994; 59: 939-952.
48. Javanmard M, Shlik J, Kennedy SH, et al. Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiat 1999; 45: 872-882.
49. Shlik J, Vasar V, Aluoja A, et al. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biol Psychiat 1997; 42: 206-212.
50. Schunck T, Erb G, Mathis A, et al. Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. Neuroimage 2006; 31: 1197-1208.
51. Eser D, Leicht G, Lutz J, et al. Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers. Hum Brain Mapp 2009; 30: 511-522.
52. Koszycki D, Zacharko RM, Le Melledo JM, Bradwejn J,. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress Anxiety 1998; 8: 1-7.
53. Kellner M, Yassouridis A, Jahn H, Wiedemann K,. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. Psychopharmacology 1997; 133: 55-61.
54. Strohle A, Holsboer F, Rupprecht R,. Increased ACTHconcentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology 2000; 22: 251-256.
55. Khan S, Liberzon I, Abelson JL,. Effects of propranolol on symptom and endocrine responses to pentagastrin. Psychoneuroendocrinology 2004; 29: 1163-1171.
56. Knott VJ, Mahoney C, Gunnarsson T, et al. Acute cholecystokinin effects on event-related potentials in healthy volunteers. Hum Psychopharmacol 2002; 17: 285-291.
57. Knott V, Mahoney C, Bradwejn J, et al. Effects of acute cholecystokinin infusion on hemispheric EEGasymmetry and coherence in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiat 2003; 27: 179-184.
58. Zwanzger P, Eser D, Volkel N, et al. Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin- tetrapeptide (CCK-4). Int J Neuropsychopharmacol 2007; 10: 285-289.
59. Beinfeld MC, Meyer DK, Brownstein MJ,. Cholecystokinin in the central nervous system. Peptides 1981; Suppl 2: 77-79.
60. Pavlasevic S, Bednar I, Qureshi GA, Sodersten P,. Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. Neuroreport 1993; 5: 225-228.
61. Carlberg M, Gundlach AL, Mercer LD, Beart PM,. Autoradiographic localization of cholecystokinin A and B receptors in rat brain using [125I]d-Tyr25 (Nle28,31)-CCK25-33S. Eur J Neurosci 1992; 4: 563-573.
62. Honda T, Wada E, Battey JF, Wank SA,. Differential gene expression of CCK(A) and CCK(B) receptors in the rat brain. Mol Cell Neurosci 1993; 4: 143-154.
63. Mercer LD, Beart PM, Horne MK, Finkelstein DI, Carrive P, and, Paxinos G,. On the distribution of cholecystokinin Breceptors in monkey brain. Brain Res 1996; 738: 313-318.
64. Zarbin MA, Innis RB, Wamsley JK, et al. Autoradiographic localization of cholecystokinin receptors in rodent brain. J Neurosci 1983; 3: 877-906.
65. Davis M,. The role of the amygdala in fear and anxiety. Annu Rev Neurosci 1992; 15: 353-375.
66. LeDoux JE, Iwata J, Cicchetti P, Reis DJ,. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. J Neurosci 1988; 8: 2517-2529.
67. Gray JA,. The neuropsychology of anxiety. Oxford: Oxford University Press; 1982.
68. Lo CM, Samuelson LC, Chambers JB, et al. Characterization of mice lacking the gene for cholecystokinin. Am J Physiol Regul Integr Comp Physiol 2008; 294: R803-R810.
69. Cohen H, Kaplan Z, Matar MA, et al. Different pathways mediated by CCK1 and CCK2 receptors: effect of intraperitonal mrna antisense oligodeoxynucleotides to cholecystokinin on anxiety-like and learning behaviors in rats. Depress Anxiety 2004; 20: 139-152.
70. Cohen H, Kaplan Z, Kotler M,. Inhibition of anxiety in rats by antisense to cholecystokinin precursor protein. Biol Psychiat 1998; 44: 915-917.
71. Yamamoto Y, Akiyoshi J, Kiyota A, et al. Increased anxiety behavior in OLETFrats without cholecystokinin-A receptor. Brain Res Bull 2000; 53: 789-792.
72. Ballaz S, Barber A, Fortuno A, et al. Pharmacological evaluation of IQM-95,333, a highly selective CCKAreceptor antagonist with anxiolytic-like activity in animal models. Brit J Pharmacol 1997; 121: 759-767.
73. Hendrie CA, Neill JC, Shepherd JK, Dourish CT,. The effects of CCKAand CCKBantagonists on activity in the black/white exploration model of anxiety in mice. Physiol Behav 1993; 54: 689-693.
74. Miyasaka K, Kobayashi S, Ohta M, et al. Anxiety-related behaviors in cholecystokinin-A, B, and ABreceptor gene knockout mice in the plus-maze. Neurosci Lett 2002; 335: 115-118.
75. Vasar E, Lang A, Harro J, et al. Evidence for potentiation by CCKantagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze. Neuropharmacology 1994; 33: 729-735.
76. Johnson NJ, Rodgers RJ,. Ethological analysis of cholecystokinin (CCKAand CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice. Psychopharmacology 1996; 124: 355-364.
77. Rataud J, Darche F, Piot O, et al. 'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice. Brain Res 1991; 548: 315-317.
78. Matto V, Harro J, Allikmets L,. The effects of cholecystokinin Aand Breceptor antagonists on exploratory behaviour in the elevated zero-maze in rat. Neuropharmacology 1997; 36: 389-396.
79. Schroeder M, Weller A,. Anxiety-like behavior and locomotion in CCK1 knockout rats as a function of strain, sex and early maternal environment. Behav Brain Res 2010; 211: 198-207.
80. Raud S, Innos J, Abramov U, et al. Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test. Psychopharmacology 2005; 181: 347-357.
81. Horinouchi Y, Akiyoshi J, Nagata A, et al. Reduced anxious behavior in mice lacking the CCK2 receptor gene. Eur Neuropsychopharmacol 2004; 14: 157-161.
82. Raud S, Runkorg K, Veraksits A, et al. Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice. Psychopharmacology 2003; 168: 417-425.
83. Jenck F, Martin JR, Moreau JL,. Behavioral effects of CCKBreceptor ligands in a validated simulation of panic anxiety in rats. Eur Neuropsychopharmacol 1996; 6: 291-298.
84. Kolik LG, Gudasheva TA, Seredenin SB,. Pharmacogenetic study of anxiolytic effects of new cholecystokinin receptor antagonists in animals with different levels of emotionality. Bull Exp Biol Med 2003; 135: 440-444.
85. Tsutsumi T, Akiyoshi J, Isogawa K, et al. Suppression of conditioned fear by administration of CCKBreceptor antagonist PD135158. Neuropeptides 1999; 33: 483-486.
86. Boden PR, Higginbottom M, Hill DR, et al. Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-Bantagonists. J Med Chem 1993; 36: 552-565.
87. Singh L, Field MJ, Vass CA, et al. The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988. Brit J Pharmacol 1992; 105: 8-10.
88. Singh L, Field MJ, Hughes J, et al. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. Brit J Pharmacol 1991; 104: 239-245.
89. Costall B, Domeney AM, Hughes J, et al. Anxiolytic effects of CCK-Bantagonists. Neuropeptides 1991; 19 Suppl: 65-73.
90. Horwell DC, Hughes J, Hunter JC, et al. Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-Bantagonists with potent anxiolytic properties. J Med Chem 1991; 34: 404-414.
91. Hughes J, Boden P, Costall B, et al. Development of a class of selective cholecystokinin type Breceptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 1990; 87: 6728-6732.
92. Chen Q, Nakajima A, Meacham C, Tang YP,. Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse. Proc Natl Acad Sci USA 2006; 103: 3881-3886.
93. Chen Q, Tang M, Mamiya T, et al. Bi-directional effect of cholecystokinin receptor-2 overexpression on stress-triggered fear memory and anxiety in the mouse. PLoS One 2010; 5: e15999: 1-12.
94. Bertoglio LJ, Zangrossi H,. Involvement of dorsolateral periaqueductal gray cholecystokinin-2 receptors in the regulation of a panic-related behavior in rats. Brain Res 2005; 1059: 46-51.
95. Zanoveli JM, Netto CF, Guimaraes FS, Zangrossi H, Jr,. Systemic and intra-dorsal periaqueductal gray injections of cholecystokinin sulfated octapeptide (CCK-8s) induce a panic-like response in rats submitted to the elevated T-maze. Peptides 2004; 25: 1935-1941.
96. Netto CF, Guimaraes FS,. Anxiogenic effect of cholecystokinin in the dorsal periaqueductal gray. Neuropsychopharmacology 2004; 29: 101-107.
97. Frankland PW, Josselyn SA, Bradwejn J, et al. Activation of amygdala cholecystokinin B receptors potentiates the acoustic startle response in the rat. J Neurosci 1997; 17: 1838-1847.
98. Hernandez-Gomez AM, Aguilar-Roblero R, Perez de la Mora M,. Role of cholecystokinin-A and cholecystokinin-B receptors in anxiety. Amino Acids 2002; 23: 283-290.
99. Izumi T, Inoue T, Tsuchiya K, et al. Effect of the selective CCKBreceptor antagonist LY288513 on conditioned fear stress in rats. Eur J Pharmacol 1996; 300: 25-31.
100. Tsutsumi T, Akiyoshi J, Hikichi T, et al. Suppression of conditioned fear by administration of CCKBreceptor antisense oligodeoxynucleotide into the lateral ventricle. Pharmacopsychiatry 2001; 34: 232-237.
101. Wang H, Spiess J, Wong PT, Zhu YZ,. Blockade of CRF1 and CCK2 receptors attenuated the elevated anxiety-like behavior induced by immobilization stress. Pharmacol Biochem Behav 2011; 98: 362-368.
102. Griebel G, Perrault G, Sanger DJ,. CCKreceptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours. Behav Pharmacol 1997; 8: 549-560.
103. Wunderlich GR, Raymond R, DeSousa NJ, et al. Decreased CCK(B) receptor binding in rat amygdala in animals demonstrating greater anxiety-like behavior. Psychopharmacology 2002; 164: 193-199.
104. Dauge V, Sebret A, Beslot F, et al. Behavioral profile of CCK2 receptor-deficient mice. Neuropsychopharmacology 2001; 25: 690-698.
105. Abramov U, Puussaar T, Raud S, et al. Behavioural differences between C57BL/6 and 129S6/SvEv strains are reinforced by environmental enrichment. Neurosci Lett 2008; 443: 223-227.
106. Abramov U, Raud S, Innos J, et al. Different housing conditions alter the behavioural phenotype of CCK(2) receptor-deficient mice. Behav Brain Res 2008; 193: 108-116.
107. Koks S, Mannisto PT, Bourin M, et al. Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. J Psychiatry Neurosci 2000; 25: 33-42.
108. Belzung C, Pineau N, Beuzen A, Misslin R,. PD135158, a CCK-Bantagonist, reduces "state," but not "trait" anxiety in mice. Pharmacol Biochem Behav 1994; 49: 433-466.
109. Derrien M, McCort-Tranchepain I, Ducos B, Rocques BP, Durleux C,. Heterogeneity of CCK-Breceptors involved in animal models of anxiety. Pharmacol Biochem Behav 1994; 49: 133-141.
110. Charney DS,. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl 2003; 417: 38-50.
111. Boden PR, Woodruff GN, Pinnock RD,. Pharmacology of a cholecystokinin receptor on 5-hydroxytryptamine neurones in the dorsal raphe of the rat brain. Brit J Pharmacol 1991; 102: 635-638.
112. Fekete M, Varszegi M, Kadar T, et al. Effect of cholecystokinin octapeptide sulphate ester on brain monoamines in the rat. Acta Physiol Acad Sci Hung 1981; 57: 37-46.
113. Itoh S, Takashima A, Katsuura G,. Effect of cholecystokinin tetrapeptide amide on the metabolism of 5-hydroxytryptamine in the rat brain. Neuropharmacology 1988; 27: 427-431.
114. Rex A, Fink H, Marsden CA,. Effects of BOC-CCK-4 and L365.260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze. Neuropharmacology 1994; 33: 559-565.
115. Paudice P, Raiteri M,. Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens. Brit J Pharmacol 1991; 103: 1790-1794.
116. Raiteri M, Paudice P, Vallebuona F,. Inhibition by 5-HT3 receptor antagonists of release of cholecystokinin-like immunoreactivity from the frontal cortex of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 111-114.
117. To CT, Bagdy G,. Anxiogenic effect of central CCKadministration is attenuated by chronic fluoxetine or ipsapirone treatment. Neuropharmacology 1999; 38: 279-282.
118. Depot M, Caille G, Mukherjee J, et al. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology 1999; 20: 177-187.
119. Vasar E, Peuranen E, Oopik T, et al. Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCKreceptors, in the elevated plus-maze. Psychopharmacology 1993; 110: 213-218.
120. Maron E, Tasa G, Toru I, et al. Association between serotonin-related genetic polymorphisms and CCK-4-induced panic attacks with or without 5-hydroxytryptophan pretreatment in healthy volunteers. World J Biol Psychiat 2004; 5: 149-154.
121. Koszycki D, Zacharko RM, Le Melledo JM, et al. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiat 1996; 40: 648-655.
122. Maron E, Toru I, Tasa G, et al. Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers. Neurosci Lett 2008; 446: 88-92.
123. Kent JM, Mathew SJ, Gorman JM,. Molecular targets in the treatment of anxiety. Biol Psychiat 2002; 52: 1008-1030.
124. Bremner JD, Innis RB, White T, et al. SPECT[I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiat 2000; 47: 96-106.
125. Malizia AL, Cunningham VJ, Bell CJ, et al. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PETstudy. Arch Gen Psychiat 1998; 55: 715-720.
126. Goddard AW, Mason GF, Almai A, et al. Reductions in occipital cortex GABAlevels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiat 2001; 58: 556-561.
127. Bradwejn J, de Montigny C,. Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones. Nature 1984; 312: 363-364.
128. Strohle A, Romeo E, di, Michele F, et al. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiat 2003; 60: 161-168.
129. Eser D, di, Michele F, Zwanzger P, et al. Panic induction with cholecystokinin-tetrapeptide (CCK-4) increases plasma concentrations of the neuroactive steroid 3alpha, 5alpha tetrahydrodeoxycorticosterone (3alpha, 5alpha-THDOC) in healthy volunteers. Neuropsychopharmacology 2005; 30: 192-195.
130. Zwanzger P, Eser D, Romeo E, et al. Changes in CCK-4 induced panic after treatment with the GABA-reuptake inhibitor tiagabine are associated with an increase in 3alpha,5alpha-tetrahydrodeoxycorticosterone concentrations. Psychoneuroendocrinology 2009; 34: 1586-1589.
131. Zwanzger P, Jarry H, Eser D, et al. Plasma gamma-amino-butyric acid (GABA) levels in cholecystokinine-tetrapeptide (CCK-4) induced anxiety. J Neural Transm 2003; 110: 313-316.
132. Yaksh TL, Furui T, Kanawati IS, Go VL,. Release of cholecystokinin from rat cerebral cortex in vivo: role of GABAand glutamate receptor systems. Brain Res 1987; 406: 207-214.
133. Harro J, Lang A, Vasar E,. Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain. Eur J Pharmacol 1990; 180: 77-83.
134. Chopin P, Briley M,. The benzodiazepine antagonist flumazenil blocks the effects of CCKreceptor agonists and antagonists in the elevated plus-maze. Psychopharmacology 1993; 110: 409-414.
135. Sheehan MJ, de BJ,. Facilitation of GABArelease by cholecystokinin and caerulein in rat cerebral cortex. Neuropeptides 1983; 3: 429-434.
136. Perez de la Mora M, Hernandez-Gomez AM, Mendez-Franco J, Fuxe K,. Cholecystokinin-8 increases K(+)-evoked [3H] gamma-aminobutyric acid release in slices from various brain areas. Eur J Pharmacol 1993; 250: 423-430.
137. Rakovska A,. Cholecystokinin-GABAinteractions in rat striatum. Neuropeptides 1995; 29: 257-262.
138. Ferraro L, Beani L, Trist D, et al. Effects of cholecystokinin peptides and GV150013, a selective cholecystokininB receptor antagonist, on electrically evoked endogenous GABArelease from rat cortical slices. J Neurochem 1999; 73: 1973-1981.
139. Godukhin O, You ZB, Herrera-Marschitz M, et al. Effect of local cholecystokinin-8 administration on extracellular levels of amino acids and glycolytic products monitored by in vivo microdialysis in the fronto-parietal cortex of the rat. Neurosci Lett 1995; 194: 29-32.
140. You ZB, Godukhin O, Goiny M, et al. Cholecystokinin-8S increases dynorphin B, aspartate and glutamate release in the fronto-parietal cortex of the rat via different receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 576-581.
141. Siniscalchi A, Rodi D, Cavallini S, et al. Effects of cholecystokinin tetrapeptide (CCK(4)) and of anxiolytic drugs on GABAoutflow from the cerebral cortex of freely moving rats. Neurochem Int 2003; 42: 87-92.
142. Goddard AW, Charney DS,. Toward an integrated neurobiology of panic disorder. J Clin Psychiat 1997; 58 Suppl 2: 4-11.
143. Jerabek I, Boulenger JP, Bradwejn J, et al. CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects. Eur Neuropsychopharmacol 1999; 9: 149-155.
144. Le Melledo JM, Bradwejn J, Koszycki D, et al. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms. Biol Psychiat 1998; 44: 364-366.
145. Hinkelmann K, Yassouridis A, Mass R, et al. CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks. J Psychiat Res 2010; 44: 1148-1153.
146. Abelson JL, Liberzon I,. Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin. Neuropsychopharmacology 1999; 21: 485-494.
147. Boulenger JP, Jerabek I, Jolicoeur FB, et al. Elevated plasma levels of neuropeptide Yin patients with panic disorder. Am J Psychiat 1996; 153: 114-116.
148. Kim H, Whang WW, Kim HT, et al. Expression of neuropeptide Y and cholecystokinin in the rat brain by chronic mild stress. Brain Res 2003; 983: 201-208.
149. Camilleri M, Carlson P, Zinsmeister AR, et al. Neuropeptide S receptor induces neuropeptide expression and associates with intermediate phenotypes of functional gastrointestinal disorders. Gastroenterology 2010; 138: 98-107.
150. Becker C, Andre J, Zeau B, et al. Melatonin MT(1/2) receptor stimulation reduces cortical overflow of cholecystokinin-like material in a model of anticipation of social defeat in the rat. Neuropharmacology 2004; 46: 1158-1167.
151. Antonelli T, Tomasini MC, Mazza R, et al. Cannabinoid CB1 and cholecystokinin CCK2 receptors modulate, in an opposing way, electrically evoked [3H]GABAefflux from rat cerebral cortex cell cultures: possible relevance for cortical GABAtransmission and anxiety. J Pharmacol Exp Ther 2009; 329: 708-717.
152. Chhatwal JP, Gutman AR, Maguschak KA, et al. Functional interactions between endocannabinoid and CCKneurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology 2009; 34: 509-521.
153. Domschke K, Zwanzger P,. GABAergic and endocannabinoid dysfunction in anxiety-future therapeutic targets? Curr Pharm Des 2008; 14: 3508-3517.
154. Jacob C, Domschke K, Gajewska A, et al. Genetics of panic disorder: focus on association studies and therapeutic perspectives. Expert Rev Neurother 2010; 10: 1273-1284.
155. Hamilton SP, Slager SL, Heiman GA, et al. Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22. Biol Psychiat 2002; 51: 591-601.
156. Domschke K, Deckert J, O'donovan MC, Glatt SJ,. Meta-analysis of COMTval158met in panic disorder: ethnic heterogeneity and gender specificity. Am J Med Genet B Neuropsychiat Genet 2007; 144B: 667-673.
157. Deckert J, Catalano M, Syagailo YV, et al. Excess of high activity monoamine oxidase Agene promoter alleles in female patients with panic disorder. Hum Mol Genet 1999; 8: 621-624.
158. Samochowiec J, Hajduk A, Samochowiec A, et al. Association studies of MAO-A, COMT, and 5-HTTgenes polymorphisms in patients with anxiety disorders of the phobic spectrum. Psychiat Res 2004; 128: 21-26.
159. Maron E, Nikopensius T, Koks S, et al. Association study of 90 candidate gene polymorphisms in panic disorder. Psychiat Genet 2005; 15: 17-24.
160. Deckert J, Nothen MM, Franke P, et al. Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. Mol Psychiat 1998; 3: 81-85.
161. Domschke K, Reif A, Weber H, et al. Neuropeptide Sreceptor gene-converging evidence for a role in panic disorder. Mol Psychiat 2011; 16: 938-948.
162. Hansen TV, Rehfeld JF, Nielsen FC,. Function of the C-36 to T polymorphism in the human cholecystokinin gene promoter. Mol Psychiat 2000; 5: 443-447.
163. Wang Z, Valdes J, Noyes R, et al. Possible association of a cholecystokinin promotor polymorphism (CCK-36CT) with panic disorder. Am J Med Genet 1998; 81: 228-234.
164. Garvey MJ, Crowe RR, Wang Z,. An association of NAGlevels and a mutation of the CCKgene in panic disorder patients. Psychiat Res 1998; 80: 149-153.
165. Koefoed P, Woldbye DP, Hansen TO, et al. Gene variations in the cholecystokinin system in patients with panic disorder. Psychiat Genet 2010; 20: 59-64.
166. Kennedy JL, Bradwejn J, Koszycki D, et al. Investigation of cholecystokinin system genes in panic disorder. Mol Psychiat 1999; 4: 284-285.
167. Hamilton SP, Slager SL, Helleby L, et al. No association or linkage between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B receptor and panic disorder. Mol Psychiat 2001; 6: 59-65.
168. Hattori E, Yamada K, Toyota T, et al. Association studies of the CTrepeat polymorphism in the 5' upstream region of the cholecystokinin Breceptor gene with panic disorder and schizophrenia in Japanese subjects. Am J Med Genet 2001; 105: 779-782.
169. Hosing VG, Schirmacher A, Kuhlenbaumer G, et al. Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. J Neural Transm Suppl 2004; 68: 147-156.
170. Hattori E, Ebihara M, Yamada K, et al. Identification of a compound short tandem repeat stretch in the 5'-upstream region of the cholecystokinin gene, and its association with panic disorder but not with schizophrenia. Mol Psychiat 2001; 6: 465-470.
171. Ebihara M, Ohba H, Hattori E, et al. Transcriptional activities of cholecystokinin promoter haplotypes and their relevance to panic disorder susceptibility. Am J Med Genet B Neuropsychiat Genet 2003; 118B: 32-35.
172. Ise K, Akiyoshi J, Horinouchi Y, et al. Association between the CCK-Areceptor gene and panic disorder. Am J Med Genet B Neuropsychiat Genet 2003; 118B: 29-31.
173. Miyasaka K, Yoshida Y, Matsushita S, et al. Association of cholecystokinin-A receptor gene polymorphisms and panic disorder in Japanese. Am J Med Genet B Neuropsychiat Genet 2004; 127B: 78-80.
174. Gelernter J, Bonvicini K, Page G, et al. Linkage genome scan for loci predisposing to panic disorder or agoraphobia. Am J Med Genet 2001; 105: 548-557.
175. Kato T, Wang ZW, Zoega T, Crowe RR,. Missense mutation of the cholecystokinin B receptor gene: lack of association with panic disorder. Am J Med Genet 1996; 67: 401-405.
176. Yamada K, Hattori E, Shimizu M, et al. Association studies of the cholecystokinin Breceptor and A2a adenosine receptor genes in panic disorder. J Neural Transm 2001; 108: 837-848.
177. Gratacos M, Costas J, de Cid R, et al. Identification of new putative susceptibility genes for several psychiatric disorders by association analysis of regulatory and non-synonymous SNPs of 306 genes involved in neurotransmission and neurodevelopment. Am J Med Genet B Neuropsychiat Genet 2009; 150B: 808-816.
178. Maron E, Kallassalu K, Tammiste A, et al. Peripheral gene expression profiling of CCK-4-induced panic in healthy subjects. Am J Med Genet B Neuropsychiat Genet 2010; 153B: 269-74.
179. Bradwejn J, Koszycki D,. Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest Suppl 2001; 234: 19-27.